NIH-FUNDED ONCOLOGY RESEARCHER
My aim as a scientist in top-ranked universities, has been to prevent and treat inflammation and cancer. Working in intensive and dynamic research environments, I have achieved success presenting and publishing with expert principal investigators. Cooperating with MDs, PhDs, and Medical Fellows, I bring dedication, enthusiasm and rigor to the exciting work of translational oncology research. I have a wide spectrum of experience in cancer therapy, including the analysis of molecular mechanisms in prevention and treatment.
RESEARCH INTEREST & BACKGROUND:
• Primary interest: Examination of novel agents in clinical trials and tumor survival induced by genotoxic chemotherapeutics. Seeking direct responsibility for conducting clinical trials.
• Graduate work: Performed in vitro evaluation of novel class of anticancer agents, the polyamine analogues, undergoing phase I clinical trials. Led to primary career focus on the elucidation of molecular mechanisms of anticancer agents.
• Postdoctoral work: Focused on clinical toxicity associated with a developing anticancer agent, perillyl alcohol. Outcome suggested that the mechanism of perillyl-induced gastrointestinal reflux in subjects in phase I drug trials could also exploit tumor cells that express a calcium-dependent NF-κB mediated survival pathway.
• Current work at the University of Wisconsin-Madison: Received NIH funding to examine genotoxic activity of cigarette smoke as prelude to inflammation associated cancer through induction of transcriptional factor NF-κB.